Clinical Trial

Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a randomized, open-label, controlled, multi-center Phase III clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate versus platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer. All enrolled patients will be randomly divided into 2 groups and continuously treated until any event that meets the criteria for end of the clinical trial.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-05-26; most recent amendment 2025-09-08.
Status change: Enrolling by Invitation → Active, Not Recruiting 2024-12-30
Status change: Not Yet Recruiting → Enrolling by Invitation 2021-12-12
Trial Details
NCT Number NCT04906993
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Cervical Cancer
Enrollment 443 participants
Start Date 2021-07-23
Primary Completion 2025-06-10 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-09